Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

27 Jun 2016 07:00

RNS Number : 2776C
Biome Technologies PLC
27 June 2016
 

27 June 2016

 

 

Biome Technologies plc

("Biome", the "Company" or the "Group")

 

Trading Update

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes a trading update for the six month period ending 30 June 2016. This update is being made ahead of the period end and in place of the trading update scheduled for the end of July. The interim results are expected to be announced on 31 August 2016.

 

Trading Update

Total Group revenues for the first half are expected to be ÂŁ2.2m (H1 2015 ÂŁ2.1m). Whilst this revenue is marginally ahead of last year's performance, it is below that of the Board's expectations. This shortfall is due to a reduced demand for already commercialised products in the Bioplastics Division and some slippage of the Stanelco RF's division's order pipeline into the second half.

 

The Group's cash position at 27 June 2016 is ÂŁ1.0m (31 March 2016: ÂŁ1.6m) reflecting the current trading activity and timing of anticipated cash receipts from work in progress in the Stanelco RF division.

 

Bioplastics Division

Revenues generated by the Bioplastics Division in the first half of 2016 totalled ÂŁ0.6m (H1 2015 ÂŁ1.0m).

It was noted in the trading update of 25 April 2016 that revenues in the Bioplastics division in the first quarter of 2016 were ÂŁ0.2m (Q1 2015: ÂŁ0.5m) reflecting the timings of campaign production runs of packaging and lidding materials for the US single-serve coffee market (coffee pods). Whilst revenues recovered in Q2 2016 to ÂŁ0.4m with some additional campaigns, it had been expected by the Board that this recovery would be stronger.

 

Biome has been developing a suite of related materials to enable coffee pod producers to sell biodegradable end products to the US consumer market. This is an important advance for the market and has received supportive media comment. The materials Biome has been developing comprise the outer packaging and the lid, ring and "non-woven" filter of the pod. Each part has entailed significant development cost both in time and in production testing and we have worked in a collaborative way with the manufacturers of the pods and packaging in the US to achieve success. The packaging and lid materials have completed their development stages and have been in full production from the middle of last year. The ring and filter materials are in the advanced stages of development and we expect to move into commercialisation by the end of this year with these materials. Whilst the second half of this year should be favourably impacted as the ring reaches its commercialisation phase, it has now become clear that the inflexion point of significant revenue generation will be later in the half year than the Board has previously expected as Biome's customers complete their own work to industrialise this innovative product.

 

Throughout this broad programme, Biome has been continually re-assessing the likely demand for the portfolio of the Bioplastics division's materials, although this is made difficult by fluctuating underlying market growth, the rise in demand for such bio-degradable products as they become available and, contrarily, improving efficiencies in our customers' production processes. The Group has just completed such a review and the Board continues to believe that the long-term outlook for these products remains very positive. In the short term, however, it believes the likely demand will be less than originally thought. This will result in a near-term fall in anticipated revenues. A similar review will be undertaken at the end of August, prior to the Group's Interim Statement.

 

Stanelco RF Technologies Division

Revenues for this division in the first half of 2016 were ÂŁ1.6m (2015: ÂŁ1.3m), slightly behind the Board's expectations. Whilst a number of the prospective orders for the second half are still being finalised, the division has a healthy enquiry book forward into 2017.

 

Group Outlook

Group revenues at the mid-year point are behind the Board's expectations. Whilst margins have been robust and the operating loss for the period is anticipated to be lower than for the same period in 2015, it will be behind the Board's expectations.

 

Whilst the Board is confident that revenue growth should accelerate in the second half of the year, it is now likely that the Group's full year performance will be significantly behind current market expectations, with the Board now expecting Group revenues for the year to 31 December 2016 to be only marginally ahead of those achieved in the prior year.

 

 

- Ends -

 

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Richard Short (Nominated Adviser)

Chris Crawford/Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

FTI Consulting

Oliver Winters

www.fticonsulting.com

Tel: +44 (0) 20 3727 1535

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTAKADNFBKDFAB
Date   Source Headline
29th Jan 20157:00 amRNSOperational Update
22nd Jan 20157:00 amRNSPre-close Trading Statement
21st Jan 20154:35 pmRNSHolding(s) in Company
11th Dec 201410:11 amRNSChange of Adviser
14th Nov 20149:58 amRNSHolding(s) in Company
4th Nov 20147:00 amRNSTrading Update
3rd Sep 20147:00 amRNSInterim Results
12th Aug 20149:36 amRNSHolding(s) in Company
31st Jul 20147:00 amRNSContract progress for RF Technologies Business
24th Jul 20143:28 pmRNSTrading Update
6th Jun 20143:56 pmRNSHolding(s) in Company
7th May 20147:00 amRNSEMI Share Option Plan
23rd Apr 201412:26 pmRNSResult of AGM and Appointment of Director
23rd Apr 20147:00 amRNSTrading Update
31st Mar 20147:00 amRNSUpdated Corporate Presentation
28th Mar 20147:02 amRNSPosting of Notice of AGM & Annual Report
27th Mar 20147:00 amRNSPreliminary Results
24th Mar 201411:43 amRNSContract for Stanelco RF Technologies Division
19th Feb 20149:01 amRNSHolding(s) in Company
24th Jan 20147:00 amRNSPre-close Trading Statement
4th Dec 20133:37 pmRNSIssue of Shares to Director
28th Nov 20131:30 pmRNSDirector/PDMR Shareholding
27th Nov 20137:00 amRNSHolding(s) in Company
4th Nov 20137:00 amRNSTrading Update
31st Oct 201312:27 pmRNSTotal Voting Rights
2nd Oct 201312:47 pmRNSIssue of Shares to a Director
27th Sep 20138:51 amRNSTR-1: Notification of Major Interest in Shares
25th Sep 201312:33 pmRNSResult of General Meeting
2nd Sep 20137:10 amRNSNotice of General Meeting
2nd Sep 20137:00 amRNSInterim Results
26th Jul 20137:00 amRNSPurchase of Shares following Consolidation
18th Jul 20137:00 amRNSInterim Management Statement
20th Jun 20132:34 pmRNSIssue of Equity
20th Jun 201312:45 pmRNSResult of General Meeting
17th Jun 201312:01 pmRNSHolding(s) in Company
17th Jun 201311:59 amRNSHolding(s) in Company
23rd May 20137:01 amRNSCapital Reorganisation
23rd May 20137:00 amRNSSettlement with Landlord in Respect of Leases
26th Apr 20137:00 amRNSIssue of shares to a Director Total Voting rights
25th Apr 20134:10 pmRNSResult of AGM
25th Apr 20137:00 amRNSTrading Update
4th Apr 20137:00 amRNSResearch Grant Award
3rd Apr 20134:35 pmRNSNotice of AGM and Annual Report and Accounts
28th Mar 20137:10 amRNSDirector's Remuneration and Consultancy agreement
28th Mar 20137:01 amRNSPreliminary Results
23rd Jan 20137:00 amRNSPre-close Trading Statement
2nd Nov 20127:00 amRNSTrading Update
1st Oct 20123:24 pmRNSCompletion of Sale
27th Sep 20122:03 pmRNSResult of General Meeting
7th Sep 20127:00 amRNSProposed Sale of stake in Biotec Holding GmbH

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.